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Background: Hypoxia-induced pulmonary vasoconstriction increases pulmonary
arterial pressure (PAP) and may impede right heart function and exercise performance.
This study examined the effects of oral nitrate supplementation on right heart function
and performance during exercise in normoxia and hypoxia. We tested the hypothesis that
nitrate supplementation would attenuate the increase in PAP at rest and during exercise
in hypoxia, thereby improving exercise performance.
Methods: Twelve trained male cyclists [age: 31 ± 7 year (mean ± SD)] performed 15
km time-trial cycling (TT) and steady-state submaximal cycling (50, 100, and 150W) in
normoxia and hypoxia (11% inspired O2) following 3-day oral supplementation with either
placebo or sodium nitrate (0.1mmol/kg/day). We measured TT time-to-completion,
muscle tissue oxygenation during TT and systolic right ventricle to right atrium pressure
gradient (RV-RA gradient: index of PAP) during steady state cycling.
Results: During steady state exercise, hypoxia elevated RV-RA gradient (p > 0.05),
while oral nitrate supplementation did not alter RV-RA gradient (p > 0.05). During 15
km TT, hypoxia lowered muscle tissue oxygenation (p < 0.05). Nitrate supplementation
further decreased muscle tissue oxygenation during 15 km TT in hypoxia (p < 0.05).
Hypoxia impaired time-to-completion during TT (p < 0.05), while no improvements were
observed with nitrate supplementation in normoxia or hypoxia (p > 0.05).
Conclusion: Our findings indicate that oral nitrate supplementation does not attenuate
acute hypoxic pulmonary vasoconstriction nor improve performance during time trial
cycling in normoxia and hypoxia.
Keywords: altitude, hypoxia, nitrate, NO, exercise, performance
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INTRODUCTION
Pulmonary hypertension is one of the most striking of all
physiological responses to hypoxia (West et al., 2013). It
results from an increase in pulmonary vascular resistance
(PVR). The mechanism of the underlying hypoxic pulmonary
vasoconstriction (HPV) is complex (Sylvester et al., 2012).
It is mediated by a hypoxia-induced increase in intracellular
calcium concentration, depolarizing smooth muscle in the walls
of pulmonary arterioles and veins PVR (Murray et al., 1990a,b;
Madden et al., 1992; Swenson, 2013). Acute exposure to severe
hypoxia (11% O2) can increase resting mean pulmonary arterial
pressure (PAP) by as much as 13–23mmHg compared to
normoxic values (Motley and Cournand, 1947; Groves et al.,
1987).
Elevation in PAP during hypoxic exposure impairs resting
cardiac function by increasing right atrial and ventricular end-
diastolic pressures, which impedes left atrial filling (Maignan
et al., 2009), an effect amplified during exercise (Swenson, 2013).
Hypoxic pulmonary hypertension further leads to ventilation-
perfusion mismatching during exercise (Gale et al., 1985; Torre-
Bueno et al., 1985). Accordingly, it was hypothesized that HPV
would account, in part, for the detrimental effect of hypoxia
on aerobic capacity (Naeije, 2011). In support, pharmacological
attenuation of HPV in hypoxia using selective vasodilators,
such as sitaxsentan, sildenafil, or bosentan, elevates arterial
O2 saturation (SaO2) and improves exercise tolerance, partly
restoring aerobic capacity toward normoxic values (Ghofrani
et al., 2004; Richalet et al., 2005; Naeije et al., 2010; Olfert
et al., 2011; Pham et al., 2012). However, the increase in arterial
oxygenation per se reported by these studies can also account for
the improved exercise performance (Anholm and Foster, 2011).
Nitric oxide (NO), generated from L-arginine by NO
synthases, is a vasodilator involved in the regulation of
pulmonary vascular tone and therefore HPV (Droma et al., 2002;
Scherrer et al., 2013). In normoxia, endothelial NOS plays a key
role in the regulation of vascular tone (Ignarro, 1989). However,
its activity is suppressed in hypoxic conditions, resulting in
decreased NO bioavailability (Bailey et al., 2010a). Such decrease
in NO bioavailability is associated with excessive hypoxic
pulmonary vasoconstriction, as seen in people susceptible to
high-altitude pulmonary edema (Berger et al., 2005). In addition
to endothelial NOS, NO can be formed through the nitrate-
nitrite-NO pathway. Dietary inorganic nitrate is absorbed by the
gastrointestinal system, excreted in the saliva and reduced to
nitrite by oral flora (Spiegelhalder et al., 1976). The nitrite is
swallowed and transformed to NO in the acid stomach, or used
as precursor for NO after intestinal absorption and transport
through the circulation elsewhere (Govoni et al., 2008). Hypoxia
facilitates the reduction of nitrite to NO (Millar et al., 1998;
Maher et al., 2008), allowing more NO to be generated in tissues
receiving less O2 or that are more metabolically active (Thomas
et al., 2001).
Oral and dietary nitrate supplementation has been shown to
reduce the O2 cost of locomotion (Larsen et al., 2007, 2011;
Bailey et al., 2009; Cermak et al., 2012a), which has been
attributed to either improved efficiency of oxidative metabolic
(Clerc et al., 2007; Larsen et al., 2011) or contractile processes
(Bailey et al., 2010b). During exercise in moderate hypoxia,
nitrate supplementation improves peripheral O2 efficiency and
phosphocreatine recovery kinetics (Vanhatalo et al., 2011;
Masschelein et al., 2012). Masschelein et al. (2012) showed that
nitrate supplementation improved muscle oxygenation during
submaximal exercise in severe hypoxia (11% O2). These studies
assessed performance during incremental exercise (Masschelein
et al., 2012) and constant load knee extension exercise (Vanhatalo
et al., 2011) to exhaustion, useful exercise paradigms for
mechanistic studies, but with limited ecological validity (Currell
and Jeukendrup, 2008).
The purpose of this study was two-fold. First, we examined
the effect of oral nitrate supplementation on pulmonary
hemodynamics at rest and during steady-state submaximal
exercise in normoxia and hypoxia. Second, we examined the
effect of oral nitrate supplementation on 15 km time trial cycling
(TT) performance in normoxia and hypoxia. We tested the
following hypothesis: elevating NO bioavailability with nitrate
attenuates the development of hypoxic pulmonary hypertension,
thereby improving right heart function and exercise performance
in severe hypoxia.
METHODS
Participants
Twelve male cyclists volunteered for this study (age: 31 ± 7
year; weight: 73.5 ± 5.9 kg; maximal aerobic power output:
381 ± 36W; power-to-weight ratio: 5.2 ± 0.6W/kg). Inclusion
criteria were being a trained cyclist living in Geneva, Switzerland
(389–450 m) and a non-smoker, with no previous history
of cardiovascular or respiratory disease and not taking any
medication. All participants trained at least 3 times/week. All
except one were active members of a competitive team and were
involved regularly in regional and/or national competitions. All
participants gave informed consent prior to participation. The
study was approved by the Research Ethics Committee of the
University Hospitals of Geneva and conformed to the standards
set by the Declaration of Helsinki.
Experimental Design
The participants underwent seven experimental testing sessions.
Following a full familiarization with the equipment, which
included a hypoxia sensitivity test (Bourdillon et al., 2014) and
a maximal cardiopulmonary exercise test (incremental cycling to
exhaustion) to assess the participant’s aerobic fitness (visit one),
the participants underwent two experimental phases (placebo
and nitrate), each consisting of three exercise sessions (visits two
to seven): (1) exercise echocardiography to assess pulmonary
hemodynamics in normoxia and hypoxia; (2) 15 km TT in
normoxia; and (3) 15 km TT in normobaric hypoxia. TTs
were separated by a ∼5 day rest period. The placebo/nitrate
supplementation was carried out in a double-blind, randomized
balanced crossover design, with a 5-day minimum washout
period. The TT sessions were conducted in an exercise physiology
laboratory, while the steady-state cycling sessions were carried
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out in an echocardiography room in the university hospital,
under similar laboratory conditions (temperature 24.1 ± 1.7◦C,
humidity 33 ± 5%, barometric pressure 721 ± 6mmHg). Before
each test, the participants refrained from caffeine for 12 h, and
heavy exercise and alcohol for 24 h.
Oral Nitrate Supplementation
Before each experimental session, the participants underwent a
3-day oral supplementation with either sodium nitrate (nitrate:
0.1mmol/kg/day, Larsen et al., 2006) or placebo (sodium
chloride, 0.1mmol/kg/day) in identical gelatin capsules in a
double-blinded, randomized order. The participants continued
the oral supplementation until all tests were completed within
each experimental phase. The participants were instructed to
avoid nitrate-rich foods during the entire study period in order
to reduce the variations in NO intake during the baseline
measurements and thus reduce noise in the collected data. The
participants were instructed to fill a qualitative dietary diary
throughout the study period to ensure compliance to this dietary
restriction.
Experimental Setup
Throughout each experimental session, the participants wore a
nose-clip and breathed through a mouthpiece attached to a low
resistance one-way non-rebreathing valve (Hans-Rudolph 2700,
Kansas City, KS, USA). The inspiratory side of the valve was
connected to a gas mixing system (Altitrainer, SMTec, Nyon,
Switzerland) from which they inspired either the normoxic or
the hypoxic gas mixture. The fraction of inspired O2 (FiO2)
was kept constant at either 0.21 (normoxia, ambient air) or 0.11
(hypoxia, in Geneva the equivalent of an altitude of ∼5000m).
The participants breathed through the same circuit in all six
experimental sessions.
Experimental Protocol
Echocardiography
The exercise echocardiography sessions comprised 10min of
instrumentation with the participant breathing room-air and
seated in semi-supine position (45% angle) on an electronically
braked cycle ergometer (Ergoselect 1200, Ergoline GmbH, Bitz,
Germany). They were then switched from room air to the gas
mixing system for the data collection. After a minimum 4min
adaptation restingmeasurements were performed after which the
participants performed three stages of steady-state submaximal
cycling at 50, 100, and 150 W (∼6min each), whilst maintaining
a constant pedaling rate of∼70 rpm.
Fifteen Kilometers Time Trial Cycling
The TT sessions comprised 20min of instrumentation with the
participants breathing room-air while seated on a bicycle fitted
to a Computrainer Pro Model trainer (RacerMate R©, Seattle, WA,
USA). The trainer was calibrated according to the manufacturer’s
instructions prior to each experimental session. The participants
performed a 5-min self-selected warm-up exercise (heart rate <
120 bpm). After return to rest they were then switched to breathe
from the gas mixing system for a 4-min post warm-up resting
baseline collection. Immediately, following the baseline, the
participants performed a 15 km TT as fast as possible. They were
free to shift gears and choose pedaling rate. Constant feedback
regarding the distance covered, but neither speed nor time, was
provided on a computer screen together with a dynamic virtual
reality environment showing a cycling avatar (Computrainer™
3D software version 3.0, Racermate). Two large ventilators were
placed ∼60 cm in front of the participants and wind velocity was
adjusted according to cycling speed.
Measurements
Expired NO Concentration
Expired endogenous NO concentration was measured during
normoxic rest in duplicate at an expired flow of 50ml/s
by chemoluminescense (FeNO+, Medisoft, Sorinnes, Belgium),
once in the placebo and once in the nitrate condition.
Echocardiography
Using an echocardiograph (Philips iE33, Andover, MA, USA)
and a S5 probe, the following indices of right ventricular
systolic function were quantified: (a) systolic right ventricle to
right atrium pressure gradient (RV-RA gradient: index of PAP),
estimated by peak tricuspid regurgitation velocity (TRV) using
the simplified Bernoulli equation (RV-RA gradient = 4TRV2);
(b) tricuspid annulus plane systolic excursion (TAPSE); and (c)
maximal systolic velocity of the tricuspid lateral annulus (S’-
wave: index of right heart contractility). For RV-RA gradient
measurements, signals were enhanced by venous injection of
agitated saline (Lopes et al., 2008). Echocardiography data
were analyzed oﬄine using special software (Xcelera, Philips,
Andover, MA, USA) by two experienced cardiologists blinded
to the conditions. Pulsed O2 saturation (SpO2) at the middle
finger of the right hand was recorded simultaneously to the
echocardiography data. These measurements were performed at
rest and during the last minute of the steady-state exercise steps.
Fifteen Kilometers Time-trial
Performance
Time-to-completion was extracted oﬄine from the
Computrainer software.
Respiratory Variables
Breath-by-breath gas exchange [O2 consumption (V˙O2) and
expired CO2 (V˙CO2)] and ventilatory flow were measured
with a metabolic system (Medgraphics CPX, Loma Linda, CA,
USA). Ventilation (V˙E) and its components tidal volume (VT)
and breathing frequency (f) were derived from the flow signal
and expressed in l/min BTPS. Partial pressure of end-tidal O2
(PETO2) and CO2 (PETCO2) were derived from the expired
O2 and CO2 signals. Prior to each experimental session the
system was calibrated using a 3-L syringe (M9474, Medikro Oy,
Finland) and precision gas mixtures of known O2 and CO2
concentrations. The ventilatory equivalent for oxygen (V˙E/V˙O2)
ratio was subsequently calculated.
Cardiovascular variables
Muscle oxygenation in the left vastus lateralis (∼15 cm proximal
and 5 cm lateral to the superior border of the patella) was
assessed by monitoring changes in oxy- and deoxy-hemoglobin
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(O2Hb and HHb, respectively) obtained with spatially resolved,
continuous wave near infrared spectroscopy (NIRS, Artinis
Oxymon, MKIII, Zetten, The Netherlands) using a source-
detector spacing of 3.8 cm and DPF of 4.0 (Duncan et al., 1995).
Muscle total Hb (THb) and delta Hb were calculated using
the following equations: THb = O2Hb + HHb (Equation 1);
delta Hb = O2Hb − HHb (Equation 2). Muscle O2Hb and
HHb were expressed asµmol changes from resting baseline
in either normoxia or hypoxia; i.e., resting normoxia for
normoxic trials and resting hypoxia for hypoxic trials. This
was done because (1) nitrate supplementation potentially alters
NIRS baseline as NO is a strong vasodilator and (2) NIRS
only gives relative values, and both reasons preclude direct
comparison between different baselines. We therefore analyzed
the effect of hypoxia and/or nitrate on the magnitude of
NIRS signal changes from the resting baseline to the exercise
condition.
Beat-to-beat arterial blood pressure (BP) was monitored using
finger plethysmography (Finometer R© MIDI, Finapress Medical
Systems, Amsterdam, The Netherlands). SpO2 was measured
using earlobe pulse oximetry (Radical-7, Masimo Corporation,
Irvine, CA, USA). Heart rate (HR) was derived from the peak-to-
peak intervals of the BP signal.
Electromyography (EMG)
EMG was recorded from the right vastus lateralis muscle.
After shaving, abrading, and degreasing the skin to lower
impedance <5 k, two circular silver-chloride (recording
diameter of 10mm) surface electrodes (Medi-Trace 100, Tyco
Healthcare Group, Mansfield, UK) were placed along the
line from the superior lateral side of the patella to the
anterior superior iliac spine at ∼100mm from the patella
with an inter-electrode distance (center-to-center) of 20mm
(2004). Electrode positions were marked on the skin for
identical placement between sessions. To minimize movement
artifacts electrodes and cables were secured with elastic bandage
and netting. The EMG signals were amplified (Bio Amp
Powerlab 26T, ADInstruments, Bella Vista, Australia), sampled
at 2 kHz, and band pass filtered (10–999Hz, LabChart version
7.2, ADInstruments, Bella Vista, Australia). The EMG root
mean square (RMS) was calculated for each single muscle
contraction (LabChart version 7.2, ADInstruments, Bella Vista,
Australia).
Blood gas variables
Arterialized earlobe capillary blood samples were taken at rest
and every 5 km during exercise. Vasodilating cream was applied
to an ear lobe 5-min prior to sampling (Decontractyl, Sanofi
Aventis, France). The ear lobe was pierced with a lancet and blood
collected in 60µL capillary tubes (MultiCap, Siemens Healthcare
Diagnostics Inc., Tarrytown, UK). Samples were analyzed within
5 s using a blood-gas analyzer (Rapidlab 248, Siemens Healthcare
Diagnostics Inc., Tarrytown, UK) for arterialized pH (pHa),
partial pressures of arterialized O2 (PaO2) and CO2 (PaCO2),
and arterialized O2 saturation (SaO2). Standard calibration was
performed prior to each experimental session using precision
calibration fluids and gas mixtures of known O2 and CO2
concentrations. Hemoglobin concentration ([Hb]) was measured
at rest prior to each exercise session on ear lobe arterialized
capillary blood samples using a double wavelength photometer
(HemoCue Hb201+, HemoCue AB, Ängelholm, Sweden). CaO2
was calculated using the Equation: CaO2 = 1.36 × [Hb] ×
(SaO2/100)+ 0.003× PaO2 (Equation 3).
With the exception of the blood gas data, which were
obtained from the analyzer’s print out, all TT data were
acquired continuously throughout each experimental session
using an analog-to-digital converter (ML880, PowerLab 16/30,
ADInstruments, Bella Vista, Australia) with commercially
available software (LabChart version 7.2, ADInstruments, Bella
Vista, Australia), and stored on a computer for later analysis.
The EMG was sampled and recorded at 2 kHz, while all other
variables were sampled and recorded at 200Hz.
Data Analysis and Statistics
Resting values were obtained by averaging the data of the last
30 s of the 4min resting periods prior to the TTs. During the
TTs, a mean value for each variable was obtained at each km, by
averaging the last 20 s of each km.
One-way ANOVA was used to compare the expired NO
concentration between placebo and nitrate conditions at
rest in normoxia with an α-level of 0.05 (Matlab R2013b,
MathWorks, Natick,MA,USA). Other resting data were analyzed
using Two-way repeated measures ANOVA for condition and
supplementation effect with an α-level of 0.05. For significant
interactions between hypoxia and nitrate, pairwise comparisons
were performed using Tuckey’s HSD post-hoc test with an
adjusted α-level of 0.0125. For exercise data, the effects of
hypoxia, nitrate, and exercise on mean cardiorespiratory and
blood gas responses at rest and during the 15 km TT were
assessed using Three-way repeated measures ANOVA with
an α-level of 0.05 (Matlab R2013b, MathWorks, Natick, MA,
USA). For significant interactions between hypoxia, nitrate,
and exercise, pairwise comparisons were performed using
Tuckey’s HSD post-hoc test with an adjusted α-level (in case
of interaction between exercise, hypoxia and nitrate an α-
level of 0.00078; in case of interaction between exercise and
hypoxia or nitrate an α-level of 0.0016; in case of interaction
between hypoxia and nitrate an α-level of 0.0125, indicated
where appropriate with a superscript B). Additionally to p-
values, Cohen’s d values (effect size) are reported for nitrate
or hypoxia effects. Cohen’s d was calculated as d = (M1 –
M2)/
√
(σ21 + σ
2
2)/2, where M1 and M2 are means of group 1
and 2; σ1 and σ2 are standard deviations of group 1 and 2.
The effect size was considered negligible when d < 0.20, small
when d ≥ 0.20, moderate when d ≥ 0.63 and large when
d ≥ 1.15. Due to missing data, the effects of hypoxia, nitrate,
and workload on RV-RA gradient, S’-wave and TAPSE were
assessed using linear mixed modeling with an α-level of 0.05
(IBM SPSS Statistics version 22.0; IBM Corporation, Armonk,
NY, USA). Post-hoc tests were performed on these variables in
case of interactions between hypoxia and nitrate using Sidak
adjustment for multiple comparisons. Data are reported as
means± SD.
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RESULTS
All 12 subjects completed the entire experimental protocol. No
side effects of oral nitrate supplementation were reported.
Resting Variables
Expired NO
During normoxic rest, 3-day oral nitrate supplementation
increased expired NO by 34± 34% compared to placebo (73.5±
24.9 ppm vs. 55.5± 26.6 ppm, p < 0.05, d = 0.70, n = 11).
Respiratory Variables
Hypoxia elevated resting VT (p = 0.017 vs. normoxia; d =
4.17) and tended to lower f (p = 0.059), but had no effect on
resting V˙E (p > 0.05, Table 1). Hypoxia lowered resting PETO2,
PETCO2, SpO2, and V˙O2 (p < 0.05 for all, vs. normoxia), but
had no effect on resting V˙CO2 (p > 0.05, Table 1). Oral nitrate
supplementation had no effect on any of the resting respiratory
variables (p > 0.05 vs. placebo).
Cardiovascular variables
No changes were observed in resting mean, systolic and diastolic
BP with either hypoxia or nitrate (p > 0.05). At rest, hypoxia
elevated HR (p = 0.05, d = 3.33, Table 1) and tended to elevate
RV-RA gradient (p = 0.064, Table 2), while TAPSE tended to
TABLE 1 | Effect of hypoxia and oral nitrate supplementation on resting
respiratory, cardiovascular, and blood gas variables.
Normoxia Hypoxia
Placebo Nitrate Placebo Nitrate
RESPIRATORY
V˙E (L/min) 16.3±4.9 16.3± 2.8 17.4±3.9 18.1±3.3
Vt (L) 0.82±0.30 0.81± 0.19 1.03±0.41* 1.09±0.39*
f (br/min) 20.5±4.5 21.2± 3.8 18.6±5.2 17.8±5.2
PETCO2 (mmHg) 36.8±4.6 37.4± 3.1 34.4±3.8* 34.1±2.4*
PETO2 (mmHg) 102.5±6.1 103.7± 4.4 43.9±5.4* 43.5±4.0*
SpO2 (%) 97±1 97± 1 83±4* 84±3*
V˙O2 (mL/min) 402±44 404± 60 339±93* 367±65*
V˙CO2 (mL/min) 450±76 456± 64 458±84 480±90
CARDIOVASCULAR
Mean BP (mmHg) 95±14 93± 10 89±11 95±10
Systolic BP (mmHg) 125±18 123± 13 118±17 128±13
Diastolic BP (mmHg) 75±12 72± 8 71±8 76±9
HR (b/min) 73±11 68± 15 81±14* 82±20*
BLOOD GAS
pH 7.47±0.03 7.46± 0.04 7.50±0.03* 7.47±0.04*
PaCO2 (mmHg) 31.4±3.7 32.9± 2.4 28.4±3.2* 29.8±2.3*
PaO2 (mmHg) 90.0±9.6 92.0± 7.3 45.9±4.5* 45.0±2.9*
SaO2 (%) 97±1 97± 1 86±5* 84±3*
[Hb] (g/L) 150±6 151± 9 150±8 152±8
CaO2 (mL O2/L) 203±7 202± 13 177±10* 174±11*
HCO−3 (mmol/l) 20.5±3.3 20.2± 3.2 19.5±4.6* 19.3±3.9*
Values are mean ± SD.
*Different from normoxia (p < 0.05).
be lower (p = 0.064 vs. normoxia). Meanwhile, nitrate tended
to elevate TAPSE (p = 0.081 vs. placebo, Table 2), but had no
effect on resting HR or RV-RA gradient (p > 0.05). No changes
were observed in S’-wave with either hypoxia or nitrate (p >
0.05).
Blood Variables
Hypoxia lowered resting PaO2, PaCO2, SaO2,and CaO2 (p <
0.001), and elevated pHa (p < 0.05; d = 3.97), while [Hb] was
unchanged (p > 0.05, Table 1). Oral nitrate supplementation
had no effect on any of the resting blood variables (p > 0.05 vs.
placebo).
Submaximal Exercise Echocardiography
(Table 2)
During steady-state exercise, hypoxia increased the RV-RA
gradient (p < 0.05 vs. normoxia; d = 7.34), while it was
unchanged with nitrate (p > 0.05 vs. placebo). Hypoxia increased
S’-wave during exercise (p < 0.001; d = 2.55), while nitrate
attenuated this rise (interaction: p < 0.05). Accordingly, post-
hoc analysis revealed that the S’-wave was lower with nitrate
in hypoxia (p < 0.05B vs. placebo hypoxia). No changes were
observed in TAPSE with either hypoxia or nitrate (p > 0.05).
Hypoxia decreased SpO2 (p < 0.001, d = 46.26 vs. normoxia)
while it was unchanged with nitrate (p > 0.001 vs. placebo).
Exercise decreased SpO2 in hypoxic conditions (p < 0.001, for
both main effect of exercise and interaction between hypoxia and
exercise, Table 2).
TABLE 2 | Effect of hypoxia and oral nitrate supplementation on indices of
right heart functions.
Normoxia Hypoxia
Placebo Nitrate Placebo Nitrate
RV-RA GRADIENT
Rest 18.6±4.3 20.3± 5.5 22.3± 7.3* 26.1±7.7*
50 W 26.0±3.0 27.5± 4.51 30.3± 6.4* 30.0±11.4*
100 W 27.3±3.6 29.5± 5.1 31.8± 8.4* 33.7±11.1*
150 W 27.5±6.3 29.4± 7.6 35.5± 6.0* 32.1±13.3*
S’-WAVE
Rest 12.1±1.6 12.3± 1.4 13.0± 3.6* 12.0±2.1*†
50 W 14.4±1.1 14.7± 1.5 19.1± 6.2* 15.8±2.7*†
100 W 15.8±1.3 17.0± 1.8 20.2± 2.9* 18.5±3.2*†
150 W 19.0±3.7 19.8± 1.1 21.7± 2.7* 20.2±2.8*
TAPSE
Rest 20.1±2.8 22.0± 2.6 18.8± 3.1 20.0±2.7
50 W 24.3±3.3 24.9± 4.3 23.9± 3.8 25.5±3.4
100 W 28.1±3.4 27.0± 4.4 28.2± 3.3 27.3±4.2
150 W 30.0±5.9 29.1± 4.7 29.0± 4.2 30.0±2.6
Values are mean ± SD. RV-RA gradient (mmHg), systolic right ventricle to right atrium
pressure gradient; S’-wave (cm/s), maximal systolic velocity of the tricuspid lateral
annulus; TAPSE (mm), tricuspid annular plane systolic excursion.
*Different from normoxia (p < 0.05).
†Different from placebo.
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Fifteen Kilometers Time-trial Cycling
Performance
Hypoxia increased the time-to-completion by 491 ± 486 s
compared to normoxic values (p < 0.001; d = 2.96). No
significant differences were observed in the time-to-completion
between placebo and nitrate during TT in normoxia (1581± 63 s
vs. 1597± 96 s, p > 0.05) and in hypoxia (2005± 309 s vs. 2155±
687 s, p > 0.05).
Respiratory Variables (Figure 1)
During TT, hypoxia lowered V˙E by 8± 32 l/min during TT (p <
0.05 vs. normoxia; d = 0.18) while nitrate elevated V˙E by 6 ± 35
l/min in both normoxic and hypoxic conditions (p < 0.001 vs.
placebo; d = 0.24).
Hypoxia decreased PETCO2 (by 10 ± 4mmHg) and PETO2
(by 59± 5mmHg) during TT (p < 0.001 for both, vs. normoxia;
d = 2.21 and d = 9.97, respectively). However, nitrate attenuated
this reduction in PETO2 with hypoxia (interaction: p < 0.05), but
had no effect on PETCO2 (p > 0.05). Post-hoc analysis revealed
PETO2 to be higher during TT in hypoxia with nitrate (p <
0.001B vs. placebo hypoxia), while no difference was observed
during TT in normoxia with nitrate (p > 0.05B vs. placebo
normoxia).
Hypoxia decreased both V˙O2 and V˙CO2 during TT (p <
0.001 vs. normoxia; d = 2.71 and d = 2.37, respectively,
Figure 1), while nitrate increased V˙O2 (p < 0.05 vs. placebo;
d = 0.14) but had no effect on V˙CO2 (p > 0.05).
Hypoxia increased V˙E/V˙O2 during TT (38.4 ± 7.6 l/lO2
vs. 55.8 ± 13.1 l/lO2, p < 0.001, d = 1.63), while nitrate
enhanced it in normoxia but not in hypoxia (interaction: p <
0.05). Accordingly, V˙E/V˙O2 was higher with nitrate in normoxia
(37.4 ± 8.2 l/lO2 vs. 39.6 ± 7.3 l/lO2, nitrate vs. placebo, p <
0.05), but it was not different in hypoxia (56.5 ± 13.8 l/lO2 vs.
54.3± 12.2 l/lO2, p > 0.05).
Cardiovascular Variables
Hypoxia decreased mean BP during 15 km TT (p < 0.001 vs.
normoxia; d = 0.54), while nitrate attenuated this decrease
(interaction: p < 0.001). Post-hoc analysis showed that hypoxia
decreased mean BP by 13 ± 14mmHg with placebo (p < 0.001B
vs. placebo normoxia), while nitrate increased BP in hypoxic
conditions by 6 ± 15mmHg (p < 0.001B vs. placebo hypoxia).
No change was observed in mean BP during TT with nitrate in
normoxia (p > 0.05 vs. normoxic placebo). Hypoxia increased
HR during TT by 10 ± 12 bpm (p < 0.001 vs. normoxia;
d = 0.42), while no change was observed with nitrate (p > 0.05).
During TT, hypoxia lowered SpO2 (p < 0.001 vs. normoxia; d =
5.09), while nitrate blunted this decrease (interaction: p = 0.018).
Specifically, SpO2 was lower with hypoxia by 33± 8% in placebo
(p < 0.001B vs. placebo normoxia) and by a lesser extent (31 ±
9%) in nitrate (p < 0.001B vs. placebo normoxia, Figure 1).
Muscular Variables (Figure 2)
There was an interaction between hypoxia and nitrate during
TT on muscle O2Hb (interaction: p < 0.05). As a result O2Hb
was lower in the nitrate hypoxia condition compared to nitrate
normoxia. Hypoxia lowered muscle delta Hb by 12 ± 14µM
(p < 0.001 vs. normoxia; d = 0.56) and tended to lower muscle
THb during TT (p = 0.053 vs. normoxia). Meanwhile, there was
a tendency for muscle delta Hb to be elevated with nitrate (p =
0.061 vs. placebo), while no difference was observed in muscle
THb (p > 0.05 vs. placebo). No differences were observed in
muscle HHb during TT with either hypoxia or nitrate (p > 0.05).
Hypoxia decreased muscle EMG RMS during TT by 62 ± 64µV
(p < 0.001 vs. normoxia), while no changes were observed with
nitrate (p > 0.05 vs. placebo).
Arterialized Blood Gas Variables (Table 3)
Hypoxia increased pH during TT (p < 0.001 vs. normoxia),
while nitrate had no effect (p > 0.05 vs. placebo). Hypoxia
decreased PaCO2, PaO2, and SaO2 during TT (p < 0.001 vs.
normoxia; d = 1.29, d = 5.83, d = 3.77, respectively),
while no changes were observed with nitrate (p > 0.05 vs.
placebo). Similarly, HCO−3 concentration was lowered during TT
in hypoxia (p = 0.013 vs. normoxia, d = 0.26), while nitrate had
no effect (p > 0.05 vs. placebo).
DISCUSSION
We examined the effects of oral nitrate supplementation on
pulmonary arterial pressure, time trial performance, and muscle
tissue oxygenation, during exercise in normoxia and hypoxia in
a group of trained cyclists. We found that, despite increased
expired NO, which suggested increased NO bioavailability,
no major improvements in right heart functions nor TT
performance were observed with oral nitrate supplementation
during exercise in normoxia and hypoxia. We found evidence of
greater muscle tissue deoxygenation during exercise in hypoxia
with nitrate supplementation. Nevertheless, these changes failed
to affect 15 km TT performance. Our findings indicate that
oral nitrate supplementation does not attenuate the development
of acute hypoxia-induced pulmonary hypertension or improve
TT performance in normoxia and acute hypoxia in well-trained
cyclists.
Hypoxic Pulmonary Vasoconstriction
NO inhalation is known to reverse HPV (Frostell et al., 1993;
Scherrer et al., 1996), while intravenous sodium nitrite infusion
(1µmol/min) has been shown to blunt the hypoxia-induced
increase in pulmonary arterial systolic pressure by ∼25% during
3 h exposure to moderate hypoxia (Kelly et al., 2014). In the
present study, we used the RV-RA gradient as a surrogate
measure of systolic pulmonary artery pressure and found it to
be elevated during steady-state exercise in hypoxia compared
to normoxic exercise (Table 2), which is indicative of HPV.
Contrary to our hypothesis, oral nitrate supplementation failed
to attenuate the RV-RA gradient at rest or during steady-
state submaximal exercise in acute hypoxia (Table 2). However,
it should be acknowledged that HPV has several temporal
components (Swenson, 2013). The second phase of the HPV
response, which contributes around two-third of the increase
in systolic pulmonary arterial pressure, only plateaus after 2 h
of exposure to hypoxia (Talbot et al., 2005). In the present
study, we assessed right heart function during acute hypoxic
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FIGURE 1 | Effect of hypoxia and nitrate on respiratory variables during 15km TT. Filled signs: Placebo, Open signs: nitrate. Mean ± SD.
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TABLE 3 | Effect of hypoxia, nitrate supplementation and exercise on
arterialized blood samples.
Normoxia Hypoxia
CON NO CON NO
pH
Rest 7.47±0.03 7.47±0.04 7.50±0.03* 7.47±0.04*
Km 5 7.41±0.05# 7.39±0.04# 7.44±0.07#* 7.44±0.05#*
Km 10 7.40±0.04# 7.39±0.05# 7.42±0.09#* 7.43±0.06#*
Km 15 7.37±0.05## 7.38±0.04## 7.42±0.09#* 7.40±0.06##*
PaO2
Rest 91.9±7.3 92.9±7.0 46.2±4.5* 44.7±2.9*
Km 5 78.8±5.1 80.3±8.8 32.8±1.5#* 34.7±4.7#*
Km 10 79.3±7.9## 81.5±6.7## 32.9±2.9#* 33.8±3.7#*
Km 15 77.6±7.5## 78.9±7.8## 33.4±2.4##* 33.3±1.5##*
PaCO2
Rest 30.9±3.4 32.8±2.4 28.1±3.1* 29.4±1.9*
Km 5 30.8±3.0# 29.4±2.6# 21.9±3.7#* 22.8±2.6#*
Km 10 27.5±2.4# 26.9±1.9# 19.5±3.1#* 20.6±2.7#*
Km 15 24.6±2.6# 24.8±1.6# 18.2±2.7#* 18.5±2.9#*
SaO2
Rest 97.4±0.6 97.3±0.8 86.2±4.7* 83.8±3.0*
Km 5 95.8±0.8 95.8±1.2 67.1±3.9#* 69.1±6.8#*
Km 10 95.7±1.0 96.0±0.7 65.6±4.2#* 68.0±5.0#*
Km 15 95.1±1.1 95.5±1.2 66.8±2.4#* 66.3±3.8#*
HCO3
Rest 23.8±0.9 24.8±2.1 24.1±1.2* 22.8±1.8*
km 5 20.9±3.0# 19.7±1.9# 18.3±3.9#* 19.0±2.8#*
km 10 19.3±2.2## 18.6±2.0## 16.5±3.9##* 17.9±4.2##*
km 15 17.0±2.4## 17.6±1.7## 16.4±3.8##* 16.1±2.5##*
Values are mean ± SD. PaO2, arterialized O2 pressure (mmHg); PaCO2, arterialized
CO2 pressure (mmHg); SaO2, arterialized O2 saturation (%); HCO
−
3 , bicarbonates
concentration (mmol/l).
*Different from normoxia (p < 0.05).
#Different from rest.
##Different from km 5, (p < 0.05 for both).
exposure (∼30min) and therefore cannot exclude effects after a
1–2 h exposure. Therefore, it is possible that the lack of major
improvements in RV-RA gradient in our study could be due
to the acute nature of our hypoxic stimulus. Alternatively, it is
possible that nitrate-nitrite-NO levels in the lungs were too low
for a significant effect on the pulmonary vasculature, even though
the large increase in expired NO would suggest the contrary.
Performance
Numerous studies examined the effect of acute or chronic
nitrate supplementation on TT performances in normoxia, and
found either improvement (e.g., Naeije et al., 2010; Masschelein
et al., 2012; Hoon et al., 2014) or no change in the time-
to-completion (Cermak et al., 2012b; Peacock et al., 2012;
Christensen et al., 2013; Boorsma et al., 2014; Glaister et al.,
2014; Hoon et al., 2014; Lane et al., 2014). A meta-analysis
of 17 studies by Hoon et al. (2013) revealed a small, but
insignificant beneficial effect of nitrate supplementation on
normoxic TT performance. In trained cyclists, Cermak et al.
(2012a) reported a∼10 s improvement in 10 km TT performance
in normoxia following a 6-day beetroot juice supplementation,
while Muggeridge et al. (2014) observed a 38 s improvement
in 16.1 km TT performance in moderate hypoxia (simulated
2500m). In agreement with these previous findings, we observed
non-significant improvements in 15 km TT performance during
normoxia (by ∼16 s) and severe hypoxia (by ∼151 s), following
3-day oral nitrate supplementation in a group of trained cyclists.
Taken together, it would appear that nitrate supplementation has
only marginal effects on time trial performance in well-trained
athletes.
Muscle Haemodynamics
Larsen et al. (2007) demonstrated an O2-sparing effect of
oral nitrate supplementation. They reported reduced V˙O2
during steady-state submaximal cycling following a 3-day nitrate
supplementation compared to placebo. In addition to liberating
bioactive NO, plasma nitrite by itself acts as both a potent
vasodilator in hypoxia (Maher et al., 2008) and as an alternative
electron acceptor, replacing O2 in respiration (Basu et al., 2008)
and thus partly accounting for the O2 sparing effect of dietary
nitrate during exercise. Accordingly, we would expect such “O2-
sparing effect” of nitrate supplementation to be reflected in
muscle tissue oxygenation, V˙O2 and performance, particularly
under hypoxic conditions.
In normoxia, Glaister et al. (2014) found no effect of nitrate
supplementation on power output, muscle tissue oxygenation,
performance, or integrated EMG activity during 20 km TT.
Likewise, Masschelein et al. (2012) reported no difference in
muscle O2Hb between a 6-day nitrate supplementation and
control during steady-state cycling in hypoxia compared to
control. However, they observed an improvement in muscle
tissue oxygenation index and reduced muscle HHb during
hypoxic exercise with nitrate, which was attributed to higher V˙E
and SpO2 associated with a respiratory effect of increased NO
(see “Respiratory effects of nitric oxide”). Meanwhile, Vanhatalo
et al. (2011) found improved phosphocreatine recovery kinetics
with nitrate supplementation, which reduced substrate utilization
and attenuated fatigue development during high intensity knee
extension inmoderate hypoxia, restoring high intensity isometric
exercise tolerance of short duration (∼24 s) to normoxic values.
From these observations, they concluded that dietary nitrate
improves skeletal muscle energetics and functional capacity
during exercise in moderate hypoxia. In contrast to these
previous findings, we found a reduction in muscle O2Hb during
the 15 kmTTwith oral nitrate supplementation, while EMGRMS
was unchanged (Figure 2). As performance was not significantly
different with nitrate supplementation, we attribute the greater
reduction in muscle tissue oxygenation to a better matching of
O2 delivery to themetabolic requirements of the workingmuscles
(Thomas et al., 2001).
Respiratory Effects of Nitric Oxide
Unexpectedly, we found higher V˙E during exercise in
both normoxia and hypoxia with nitrate supplementation,
accompanied by higher SpO2 during exercise in hypoxia.
Our findings confirm previous reports of increased SpO2
(by 1.5–3.5%) with nitrate supplementation during TT in
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FIGURE 2 | Effect of hypoxia and nitrate on muscular variables during 15km TT. Filled signs: Placebo, Open signs: nitrate. Mean ± SD.
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normoxia and also steady state submaximal cycling in hypoxia
(Masschelein et al., 2012; Puype et al., 2015). However, in
contrast to our data, Masschelein et al. (2012) did not find any
changes in V˙E during hypoxic exercise with nitrate, while Puype
et al. (2015) did not report any V˙E values. At the level of the
peripheral chemoreceptors nNOS-catalyzed production of NO
is thought to be an O2-dependent process, with NO exerting
an inhibitory influence on the carotid body activity (Prabhakar
and Semenza, 2012), a mechanism difficult to reconcile with our
observation of increased V˙E with oral nitrate supplementation.
The possible role of nitrate supplementation in non-NOS
dependent formation of NO and ventilation during exercise
warrants further investigation.
Responders vs. Non-responders?
Alternatively, a potential explanation for the lack of improvement
in performance could be the existence of responders and
non-responders to oral nitrate supplementation, perhaps in
line with differences in training status. In support, data
from Bescós et al. (2012) showed that 7 out of 13 trained
athletes were non-responders, with only small elevations in
plasma nitrate concentration observed following a 3-day nitrate
supplementation. Similarly, Boorsma et al. (2014) reported that
only 2 of their 8 runners improved 1500m running performance
following an 8-day nitrate supplementation. Likewise, 8 out
of 12 of our participants improved their normoxic 15 km
TT performance with oral nitrate supplementation, while 7
participants improved their times with nitrate supplementation
in hypoxia. Trained athletes have higher plasma nitrate and
nitrite concentrations, and express more muscle nNOS protein
compared to untrained controls (Poveda et al., 1997; McConell
et al., 2007). These findings led, Wilkerson et al. (2012)
to speculate that the elevated plasma nitrate and nitrite
concentrations seen in highly trained athletes, would lower the
impact of oral nitrate on NO bioavailability in these individuals.
They further speculated that increased muscle nNOS activity
could lessen the importance of the nitrate-nitrite-NO pathway
on NO production. Recently, Porcelli et al. (2014) observed a
greater reduction in the O2 cost of exercise and an improvement
in 3-km performance in individuals with low aerobic fitness
compared to those with high aerobic fitness following a 6-day
nitrate supplementation (5.5mmol/day). The authors concluded
that the ergogenic effects of nitrate supplementation depend on
the individual’s aerobic fitness level and are related to the relative
changes in plasma nitrate and nitrite concentrations. Since the
participants in our study were well-trained athletes it is therefore
possible that their training status and associated high muscle
nNOS activity might have, in part, attenuated any effects of oral
nitrate supplementation on TT performance.
Methodological Considerations
An important methodological consideration when interpreting
our findings is the lack of plasma nitrate and nitrite
measurements in our study. In recent years, numerous
studies have assessed the effects of acute and chronic nitrate
supplementation using sodium nitrate (∼0.1–0.3mmol/kg/day
Larsen et al., 2006; Bescós et al., 2012) or beetroot juice
(∼5.5–9.6mmol/day, Bailey et al., 2009; Lansley et al., 2011;
Vanhatalo et al., 2011; Bond et al., 2012; Cermak et al., 2012b;
Fulford et al., 2013; Kelly et al., 2013, 2014), and reported
increases in plasma nitrate (∼500%) and nitrite (∼40–140%),
regardless of supplementation duration (i.e., from a single
dose to 15 days of supplementation). In the present study,
we observed a 30% increase in expired NO, a measure of NO
bioavailability at the level of the lung, following oral nitrate
supplementation (0.1mmol/kg/day, i.e., an average individual
dose ∼7.3mmol/day). Since the oral nitrate supplementation
regimen used in the present study was comparable those studies
which were successful in elevating plasma levels of nitrate and
nitrite, we contend that nitrate and nitrite bioavailability was
likely to be elevated in our subjects.
Another critique is the use of systolic RV-RA gradient as a
surrogate index for PAP in the present study. Since changes
in the RV-RA gradient are influenced directly by changes in
cardiac output, and are subject to measurement errors (Fisher
et al., 2009), they do not necessarily reflect changes in PVR.
Nevertheless, our work is the first to combine the study of the
effect of nitrate supplementation on performance and on right
heart function. The next step would be to invasively measure
PAP using catheterization, which is ethically questionable in
healthy well-trained athletes, especially given the expected
limited beneficial effects of nitrate.
We used ear-lobe arterialized bloodwhich does not necessarily
faithfully reflect arterial blood saturation, specifically during
heavy exercise when sampling is difficult. The arterial-end-tidal
oxygen and CO2 differences suggest that some contamination
with ambient air occurred. However, our interpretations of
results would not radically change if PaO2 and PaCO2 were
slightly over-, respectively underestimated.
CONCLUSIONS
We found that 3-day oral nitrate supplementation elevated
expired NO but did not improve right heart function during
hypoxic exercise. Despite increased NO bioavailability we did
not observe an improvement in 15 km time trial performance in
normoxia and severe hypoxia with nitrate supplementation. Our
findings do not support nitrate supplementation in preventing
the development of hypoxia-induced pulmonary hypertension
and improving exercise performance in hypoxia in trained
athletes.
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